Post-earnings recap
Reported
Thu, Aug 6, 2026
EPS actual
$2.37
EPS est.
$1.34
EPS surprise
+76.87%
1-day move
-0.80%
Ligand Pharmaceuticals reported strong earnings with a significant EPS beat, driven by growth in royalty revenue. However, the stock reacted negatively, declining by 0.8%. This could indicate that investors were looking for even stronger revenue figures or additional guidance on future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.37 | N/A | +76.87% |
| Revenue | $64M | N/A | N/A |
| Royalty Revenue Growth | 32% | N/A | N/A |
Management expressed confidence in the company's growth trajectory, highlighting the positive impact of recent acquisitions. They also noted the upcoming catalysts that could drive future performance.
The acquisition of XOMA Royalty is expected to contribute approximately $0.50 to adjusted EPS in H2 2026.
We are entering a catalyst-rich period with multiple FDA approvals and trial readouts expected over the next 18 months.
Ligand Pharmaceuticals Incorporated (LGND) is a healthcare company focused on developing and commercializing technologies to enhance drug discovery and development. With a market cap of $6 billion, Ligand plays a crucial role in the pharmaceutical industry by providing innovative solutions that can improve patient outcomes and drive efficiency in drug development.
Last quarter
In Q1 2026, Ligand reported an EPS of $1.63, significantly beating expectations by 66.84%. However, the stock price fell 9.55% the following day, indicating potential concerns despite strong earnings.
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+288.65%
Avg 1-day reaction
+1.63%
Investors are cautiously optimistic about Ligand's upcoming earnings report, given its strong track record of beating EPS estimates. However, the lack of analyst estimates and management guidance adds uncertainty to market expectations.
Bull case
If Ligand continues its trend of beating EPS estimates, it could lead to a positive market reaction and renewed investor confidence.
Bear case
Concerns about revenue growth or potential operational challenges could lead to a negative reaction, especially given the recent stock price decline.
The print will turn on these.
Q1
What will the EPS be this quarter, and how does it compare to previous quarters?
Given Ligand's history of beating EPS estimates, the market will closely watch this figure to gauge ongoing performance.
Q2
What insights can management provide about revenue growth and future guidance?
Investors will be looking for clarity on revenue trends, which are critical for assessing the company's growth trajectory.
—
Est. EPS
$3.08
Est. Rev
$7.2B
Impl. Move
±4.0%
Why consensus could be wrong
The Street may be underestimating Ligand's ability to sustain high EPS growth due to its innovative drug development technologies.
Supporting evidence
Ligand has consistently beaten EPS estimates in the past, indicating strong operational performance.
The options market is pricing in a larger move than historical averages, suggesting that investors are overly cautious.
The recent drop in stock price following strong earnings may indicate a mispricing of the company's growth potential.
Key risk
If Ligand's EPS comes in significantly above $2.00, it could challenge the current cautious sentiment and lead to a reevaluation of growth prospects.
Pre-commit to what would confirm each case.
The core debate this quarter revolves around whether Ligand can maintain its strong earnings performance amid potential revenue growth challenges.
Bull confirmed if
An EPS of $2.00 or higher would confirm the bull case and suggest continued strong performance.
Bear confirmed if
An EPS below $1.50 could confirm the bear case, raising concerns about the company's growth prospects.
What the market is pricing for the move.
Implied Move
±15.86%
Historical Avg
±5.0%
The options market is pricing in a significant potential move in either direction, indicating heightened uncertainty ahead of the earnings report.
Options are pricing ±15.9% while LGND has averaged ±5.0% over the last 8 prints — setup is pricing rich.
ATM IV
0.4%
30d HV
47.7%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$1.5M
5,000 sh
1 insider
Net
$1.5M
Net selling
Most Active Insiders· 6 open-market trades
$1.5M
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
116.13%
of float
Insider
2.34%
of float
Holders
550
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
3,100,996 sh · $909.4M
15.56%
4.7%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Ligand beats expectations, history suggests the stock could rise by about 1.84% on the following day, confirming positive investor sentiment.
In line / cautious
If results are in line with expectations, the stock may experience a muted reaction as investors assess management's commentary.
Miss
If Ligand misses expectations, history suggests a potential decline of around 9.55%, reflecting investor disappointment.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
1 buy·0 sells
Members
1
House only
Est. Notional
$1,001.00–$15,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Recent Transactions
Oct 2, 2026 · @ $303.54
1,976 sh
$599,803.73
Oct 2, 2026 · @ $304.52
1,535 sh
$467,431.14
Oct 2, 2026 · @ $302.51
833 sh
$251,991.41
Oct 2, 2026 · @ $306.18
404 sh
$123,698.09
Oct 2, 2026 · @ $307.19
235 sh
$72,189.91
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Invesco Ltd.
1,201,644 sh · $352.4M
6.03%
45.9%
Vanguard Portfolio Management LLC
1,138,316 sh · $333.8M
5.71%
3.5%
Jupiter Topco LLC
1,040,578 sh · $305.2M
5.22%
100.0%
Vanguard Capital Management LLC
870,950 sh · $255.4M
4.37%
2.7%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net buying
Recent Transactions
Traded May 29, 2026 · disclosed Jun 8, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.